Microbiome: First bacteria we meet can keep us out of hospital
Researchers at University College London and the Sanger Institute investigated the earliest stages in our body's colonisation by bacteria, fungi and more.They collected stool samples from 1,082 newborns in the first week of life. The team then performed a massive genetic analysis on all the DNA in the samples to work out exactly which species were present and how common they were in each child.They then tracked what happened to those babies, using hospital data, for the next two years.
One particular early inhabitant of the human body, Bifidobacterium longum, seemed to have a protective effect.Only 4% of babies with this species would spend a night in hospital with a lung infection over the next two years. Babies with different starter-bacteria were two-to-three times more likely to need to stay in hospital.It is the first data to show the formation of the microbiome affects the risk of infection."I think it's really phenomenal. It's amazing to be able to show this. I'm excited," Prof Nigel Field, from UCL, told the BBC.
How are these bacteria doing it?
The most likely culprit for children ending up in hospital is respiratory syncytial virus (RSV), but what joins the dots between this and B. longum?That is the "million dollar question" for Prof Field.We know B. longum starts off digesting breast milk which both contains food for the baby and encourages good bacteria. The exact details have not yet been worked out, but either the bacteria themselves or the compounds they make by digesting food are interacting with the immune system "and are influencing the way in which the immune system matures and is able to recognise friend from foe," according to Prof Field.The protective bacteria were found only in babies that came into the world via a vaginal delivery rather than a caesarean. Even then they were not discovered after every vaginal delivery.The researchers say their findings do not justify the practice of vaginal seeding, where some new parents smear babies with a swab taken from the vagina.
The good bacteria seem to be coming from the end of the mother's digestive system, an idea known in the field as the "first lick"."I feel pretty confident in saying that vaginal seeding is not a good thing," said Prof Field.However, the long-term ambition is to come up with microbial therapies – like a probiotic yogurt – that could be given to babies to set their microbiomes on a healthy path.Prof Louise Kenny, from the University of Liverpool and a consultant obstetrician and gynaecologist, said: "A caesarean section is often a life-saving procedure, and can be the right choice for a woman and her baby."She said that while the benefit was seen only in babies born vaginally, it was not in every child born that way so "further research is needed to create a full, nuanced picture".
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
24 minutes ago
- BBC News
AI designs new superbug-killing antibiotics for gonorrhoea and MRSA
Artificial intelligence has invented two new potential antibiotics that could kill drug-resistant gonorrhoea and MRSA, researchers have drugs were designed atom-by-atom by the AI and killed the superbugs in laboratory and animal two compounds still need years of refinement and clinical trials before they could be the Massachusetts Institute of Technology (MIT) team behind it say AI could start a "second golden age" in antibiotic discovery. Antibiotics kill bacteria, but infections that resist treatment are now causing more than a million deaths a antibiotics has helped bacteria evolve to dodge the drugs' effects, and there has been a shortage of new antibiotics for have previously used AI to trawl through thousands of known chemicals in an attempt to identify ones with potential to become new antibiotics. Now, the MIT team have gone one step further by using generative AI to design antibiotics in the first place for the sexually transmitted infection gonorrhoea and for potentially-deadly MRSA (methicillin-resistant Staphylococcus aureus).Their study, published in the journal Cell, interrogated 36 million compounds including those that either do not exist or have not yet been trained the AI by giving it the chemical structure of known compounds alongside data on whether they slow the growth of different species of AI then learns how bacteria are affected by different molecular structures, built of atoms such as carbon, oxygen, hydrogen and approaches were then tried to design new antibiotics with AI. The first identified a promising starting point by searching through a library of millions of chemical fragments, eight to 19 atoms in size, and built from there. The second gave the AI free reign from the design process also weeded out anything that looked too similar to current antibiotics. It also tried to ensure they were inventing medicines rather than soap and to filter out anything predicted to be toxic to used AI to create antibiotics for gonorrhoea and MRSA, a type of bacteria that lives harmlessly on the skin but can cause a serious infection if it enters the manufactured, the leading designs were tested on bacteria in the lab and on infected mice, resulting in two new potential drugs. "We're excited because we show that generative AI can be used to design completely new antibiotics," Prof James Collins, from MIT, tells the BBC."AI can enable us to come up with molecules, cheaply and quickly and in this way, expand our arsenal, and really give us a leg up in the battle of our wits against the genes of superbugs."However, they are not ready for clinical trials and the drugs will require refinement – estimated to take another one to two year's work – before the long process of testing them in people could begin. Dr Andrew Edwards, from the Fleming Initiative and Imperial College London, said the work was "very significant" with "enormous potential" because it "demonstrates a novel approach to identifying new antibiotics".But he added: "While AI promises to dramatically improve drug discovery and development, we still need to do the hard yards when it comes to testing safety and efficacy."That can be a long and expensive process with no guarantee that the experimental medicines will be prescribed to patients at the are calling for AI drug discovery more broadly to improve. Prof Collins says "we need better models" that move beyond how well the drugs perform in the laboratory to ones that are a better predictor of their effectiveness in the is also an issue with how challenging the AI-designs are to manufacture. Of the top 80 gonorrhoea treatments designed in theory, only two were synthesised to create Chris Dowson, at the University of Warwick, said the study was "cool" and showed AI was a "significant step forward as a tool for antibiotic discovery to mitigate against the emergence of resistance".However, he explains, there is also an economic problem factoring into drug-resistant infections - "how do you make drugs that have no commercial value?"If a new antibiotic was invented, then ideally you would use it as little as possible to preserve its effectiveness, making it hard for anyone to turn a profit.
Reuters
24 minutes ago
- Reuters
Lilly to hike UK price of Mounjaro weight-loss drug by 170%
SEATTLE, Aug 14 (Reuters) - Eli Lilly (LLY.N), opens new tab will raise the UK list price of its weight-loss treatment Mounjaro by up to 170%, it said on Thursday, amid a White House push to get drugmakers to raise medicine prices in Europe to allow for price cuts in the United States. The new price, which also applies to Lilly's type 2 diabetes medicine that has the same name, is effective from September. The price for a month's supply of the highest dose of the medicine will increase from £122 to £330, Lilly said. The higher price will affect those who pay for Mounjaro privately, but will not affect those prescribed the medicine through the British public healthcare system, which has a separate deal, a Lilly spokesperson said. The U.S. drugmaker said that when it launched Mounjaro in Britain it agreed to a list price "significantly below" that in its three other European markets to prevent delays in availability through Britain's National Health Service (NHS). "We are now aligning the list price more consistently," Lilly said. The move reflects how the pharmaceutical industry is navigating policy changes in the United States, by far its most lucrative market, where President Donald Trump is pushing for lower domestic prices and encouraging price hikes overseas. Last week Eli Lilly CEO David Ricks told an investor call that parity between U.S. and European drug pricing was desirable in the long run, though he warned that European governments "are not signing up to pay more for drugs". The U.S. pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. Trump says he wants to narrow this gap to stop Americans from being "ripped off." Reuters reported last week that the Trump administration has been talking to drugmakers about ways to level the playing field for medicine prices. A list price is set by the drug manufacturer before any rebates or discounts. Lilly said it was working with private UK healthcare providers, such as online pharmacies, who can set their own prices, to ensure continued access to the medicines. Lilly launched Mounjaro in the UK in February last year, while rival Novo Nordisk's Wegovy treatment has been available in the country since September 2023.
The Independent
an hour ago
- The Independent
Death of girl left alone by fake ID worker was unlawful, jury inquest concludes
The death of a teenage girl, who was left alone at a children's mental health ward by an inexperienced agency worker using fake ID, has been ruled as an unlawful killing by an inquest jury. Ruth Szymankiewicz was being treated for an eating disorder at Huntercombe Hospital in Berkshire and had been placed under strict one-to-one observation when on February 12 2022, she was left on her own by the member of staff responsible for watching her. The 14-year-old was able to shut herself in her bedroom at the hospital's psychiatric intensive care unit – also known as Thames ward – where she self-harmed. She died two days later at John Radcliffe Hospital in Oxford. On Thursday, an inquest jury sitting at Buckinghamshire Coroner's Court in Beaconsfield returned a conclusion of unlawful killing. 'Ruth was not prevented from accessing the harmful material which could be used to self-harm,' the jury foreman told the hearing. 'Ruth's care was insufficient to allow for discharge.' The foreman added Ms Szymankiewicz's parents were not given 'adequate information' about her care on the ward. Jurors could be seen crying as they recorded their conclusion, as well as the coroner and members of the family. The agency worker responsible for watching Ms Szymankiewicz – a man then known as Ebo Acheampong – had never worked in a psychiatric hospital environment before coming to Huntercombe on February 12 2022 for his first shift. A police investigation later found he was hired by the Platinum agency – which supplied staff for Huntercombe Hospital – under a false name. Mr Acheampong never returned to work at the hospital following the incident and fled the UK for Ghana. The court heard the ward was missing at least half of its staff on the day Ms Szymankiewicz, who had self harmed several times in the past, was left unsupervised. Mr Acheampong was originally working on a different ward, but was asked to join the team on Thames ward because they were so short-staffed nurses could not go on breaks, jurors were previously told. A risk management form known as a 'Datix incident' had been filed on the day by Michelle Hancey – a support worker with 18 years' experience at Huntercombe – who raised concerns the Thames ward team would 'fail to monitor patients on prescribed special observation because of staff shortage'. During the inquest, jurors were shown CCTV footage of the moment Mr Acheampong left Ms Szymankiewicz unsupervised while she sat in the ward's lounge watching TV, enabling her to leave the room. She had been placed on the 'level three observation' plan following earlier incidents of self-harm – meaning she had to be kept within eyesight at all times. In the footage, Mr Acheampong can be seen leaving the room repeatedly – at first only for seconds at a time, then for two minutes – prompting the teenager to walk up to the door and look into the lobby, seemingly waiting for the opportunity to leave the room. She was last captured on CCTV walking out of the ward's day room 'completely on her own' before going straight to her bedroom and closing the door behind her, coroner Ian Wade KC told the inquest. Around 15 minutes passed before a nurse discovered the teenage girl and raised the alarm. Huntercombe Hospital had been inspected twice by the Care Quality Commission (CQC) prior to the incident, the inquest previously heard. It was rated as 'overall inadequate' in a CQC report dated February 2021. Active Care Group, which owned Huntercombe at the time of Ms Szymankiewicz's death, has since closed the facility.
